地特胰岛素介绍.pptVIP

* * The Levemir? Lectures – from clinical trials to clinical experience * Just as we saw with the type 1 diabetes studies, there is a remarkably consistent weight advantage with Levemir?. In the type 2 studies comparing Levemir? with NPH, there has consistently been only about half the weight gain with Levemir? as with NPH. The comparison with glargine is not strictly comparable to the other studies here as it was a 12- as opposed to 6-month study and it mixes patients on once- and twice-daily Levemir? and compares them with once-daily glargine. Still this shows significantly less weight gain with Levemir?, and those patients who completed on once-daily Levemir? in this study gained 2.3 kg, compared with the 3.9 kg gain in the once-daily glargine group, although these were not randomised cohorts. * This slide animates to superimpose the regression lines In a new analysis of weight gain stratified by BMI in the type 2 studies there is a suggestion that detemir’s advantage increases with increasing obesity. Abstract accepted at ADA 2005 The advantage of less weight gain increases with baseline obesity when insulin detemir rather than NPH insulin is added to oral agents in type 2 diabetesHermansen K and Tamer SC Diabetes 2005;54(Suppl 1):A67 Insulin treatment is often associated with unwanted weight gain, which may be a problem in already overweight type 2 diabetes patients. Clinical studies have consistently shown that insulin detemir is associated with no weight gain in type 1 diabetes and with less weight gain than NPH insulin in type 2 diabetes. However, it is not known whether this benefit is dependent on body mass index (BMI) at initiation of treatment. Therefore a post-hoc analysis of data from a study of 475 insulin-nave type 2 diabetes patients was performed, analysing weight change in relation to baseline BMI. Patients received insulin detemir or NPH insulin twice-daily (morning and evening) as add-on to existing treatment with oral blood glucose lowering